MedTrace Logo

P.Acnes Colony Count Following Subdermal Cefazolin

NCT03853096 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-02-25

No results posted yet for this study

Summary

The specific outcome is to determine whether the colony count of Propionibacterium acnes, one of the commonest causes of shoulder infection and not eradicated by conventional forms of surgical preparatory solutions and antibiotics, in a shoulder surgical wound will be altered by the use of subdermal cefazolin.

Conditions

  • Surgical Site Infection
  • Microbial Colonization

Interventions

DRUG

Cefazolin

Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • William Regan · UBC clinical professor in orthopaedics

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-04-01
Completion
2020-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03853096 on ClinicalTrials.gov